Harpoon Therapeutics IncChange company Symbol lookupSelect an option...HARP Harpoon Therapeutics IncDARE Dare Bioscience IncREXR-C Rexford Industrial Realty IncAQNA Algonquin Power & Utilities CorpNAOV Nanovibronix IncIOT Samsara IncGSIT GSI Technology IncGME GameStop CorpCMBM Cambium Networks CorpS SentinelOne IncGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 0.74x
- Price/Book (MRQ)
- 36.01x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Scott D. Myers
- Julie Marie EastlandPres.
- Frank J. LanzaCFO
- Luke WalkerOther
- Joseph S. Bailes
Address
- 131 Oyster Point Blvd Ste 300
- South San Francisco, CA 94080-1910
- Phone: (650) 443-7400
- Fax: (302) 636-5454
- https://www.harpoontx.com/
Insider Trading
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.